Clinical Trial Update: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) [Phase 3]

View source ↗

Summary

Phase 3 trial results update for vorapaxar (TRA 2°P-TIMI 50) in patients with atherosclerosis assessing prevention of heart attack and stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Ischemia
• Myocardial Infarction
• Peripheral Arterial Disease
• Stroke

Drugs mentioned

• Vorapaxar (vorapaxar)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Atherosclerosis, Ischemia | Phase 3 | Status: COMPLETED | Results posted: 2014-06-18